SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD

Key Takeaways SRPT's phase III EMBARK study showed statistically significant gains across major functional endpoints.Sarepta Therapeutics said ~52 Elevidys patients kept NSAA scores above baseline three years post-infusion.SRPT reported disease progression slowed 73% by TTR and 70% by 10MWR versus external controls.Sarepta Therapeutics (SRPT) announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating Elevidys in ambulatory individuals with Duchenne muscular dystrophy ( ...